Now that the vascular hypothesis of migraine is no longer the prevailing theory 
of migraine pathogenesis, there is interest in developing acute migraine 
treatments that act exclusively on non-vascular targets. There is a large 
percentage of non-responders to current acute migraine treatments and the 
vasoconstriction associated with triptans limit their use in patients with 
pre-existing cardiovascular risk factors. Preferential 5-HT1F agonists have 
shown promising results in in vitro and early proof-of-concept trials. 
Lasmiditan, a highly selective 5-HT1F agonist, has completed two Phase III 
randomized, double blind, placebo-controlled clinical trials, with a third - a 
long-term, open-label safety study - still underway. Research to date suggests 
lasmiditan lacks vasoconstrictive properties and may be a safe and effective 
treatment option in patients refractory to current acute migraine medications or 
who have cardiovascular risk factors.